Display options
Cite
Sun YN, Zhang ZY, Zeng YC, et al. Comparative efficacy of whole-brain radiotherapy with and without elemene liposomes in patients with multiple brain metastases from non-small-cell lung carcinoma. Curr Oncol. 2016;23(4):e377-82doi: 10.3747/co.23.3183.
Sun, Y. N., Zhang, Z. Y., Zeng, Y. C., Chi, F., Jin, X. Y., & Wu, R. (2016). Comparative efficacy of whole-brain radiotherapy with and without elemene liposomes in patients with multiple brain metastases from non-small-cell lung carcinoma. Current oncology (Toronto, Ont.), 23(4), e377-82. https://doi.org/10.3747/co.23.3183
Sun, Y N, et al. "Comparative efficacy of whole-brain radiotherapy with and without elemene liposomes in patients with multiple brain metastases from non-small-cell lung carcinoma." Current oncology (Toronto, Ont.) vol. 23,4 (2016): e377-82. doi: https://doi.org/10.3747/co.23.3183
Sun YN, Zhang ZY, Zeng YC, Chi F, Jin XY, Wu R. Comparative efficacy of whole-brain radiotherapy with and without elemene liposomes in patients with multiple brain metastases from non-small-cell lung carcinoma. Curr Oncol. 2016 Aug;23(4):e377-82. doi: 10.3747/co.23.3183. Epub 2016 Aug 12. PMID: 27536187; PMCID: PMC4974044.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2016 Aug;23(4):e377-82. doi: 10.3747/co.23.3183. Epub 2016 Aug 12.

Comparative efficacy of whole-brain radiotherapy with and without elemene liposomes in patients with multiple brain metastases from non-small-cell lung carcinoma.

Current oncology (Toronto, Ont.)

Y N Sun, Z Y Zhang, Y C Zeng, F Chi, X Y Jin, R Wu

Affiliations

  1. Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, P.R.C.

PMID: 27536187 PMCID: PMC4974044 DOI: 10.3747/co.23.3183

Abstract

PURPOSE: We explored and compared the clinical effects of whole-brain radiotherapy (wbrt) with and without elemene liposomes in patients with multiple brain metastases from non-small-cell lung carcinoma (nsclc).

METHODS: We retrospectively analyzed 62 patients with multiple brain metastases from nsclc who received wbrt (30 Gy in 10 fractions) at Shengjing Hospital of China Medical University from January 2012 to May 2013. In 30 patients, elemene liposomes (400 mg) were injected intravenously via a peripherally inserted central catheter for 21 consecutive days from the first day of radiotherapy. Overall survival (os) and nervous system progression-free survival (npfs) for the two groups were compared by Kaplan-Meier analysis. Factors influencing npfs were examined by Cox regression analysis. Chi-square or Fisher exact tests were used for group comparisons.

RESULTS: The median os was 9.0 months in the wbrt plus elemene group and 7.8 months in the wbrt-alone group (p = 0.581); the equivalent median npfs durations were 5.2 months and 3.7 months (p = 0.005). Patient treatment plan was an independent factor associated with npfs (p = 0.002). Tumour response and disease-control rates in the wbrt plus elemene group were 26.67% and 76.67% respectively; they were 18.75% and 62.5% in the wbrt group (p = 0.452). Compared with the patients in the wbrt-alone group, significantly fewer patients in the wbrt plus elemene group developed headaches (p = 0.04); quality of life was also significantly higher in the wbrt plus elemene group both at 1 month and at 2 months (p = 0.021 and p = 0.001 respectively).

CONCLUSIONS: The addition of elemene liposomes to wbrt might prolong npfs in patients with multiple brain metastases from nsclc, while also reducing the incidence of headache and improving patient quality of life.

Keywords: Elemene liposomes; multiple brain metastases; non-small-cell lung carcinoma; whole-brain radiotherapy

References

  1. Clinics (Sao Paulo). 2015 Aug;70(8):556-62 - PubMed
  2. Drug Dev Ind Pharm. 2005 Sep;31(8):769-78 - PubMed
  3. Evid Based Complement Alternat Med. 2014;2014:604152 - PubMed
  4. J Pharm Pharmacol. 2009 Dec;61(12):1653-6 - PubMed
  5. Chin J Integr Med. 2012 Nov;18(11):813-23 - PubMed
  6. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Sep;20(9):645-8 - PubMed
  7. Anticancer Res. 2013 Jan;33(1):65-76 - PubMed
  8. Front Pharmacol. 2012 Jan 09;2:94 - PubMed
  9. Evid Based Complement Alternat Med. 2012;2012:259523 - PubMed
  10. J Cell Mol Med. 2015 Mar;19(3):630-41 - PubMed
  11. Zhonghua Zhong Liu Za Zhi. 1996 Nov;18(6):464-7 - PubMed
  12. Clin Cancer Res. 2008 Jan 1;14(1):162-8 - PubMed
  13. Chin J Cancer. 2014 Feb;33(2):96-104 - PubMed
  14. Int J Nanomedicine. 2015 Feb 02;10:975-99 - PubMed
  15. Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 - PubMed
  16. Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1391-6 - PubMed
  17. Chin J Cancer. 2015 Sep 14;34(11):488-95 - PubMed
  18. Cancer Biother Radiopharm. 2012 Feb;27(1):56-64 - PubMed
  19. Thorac Cardiovasc Surg. 2008 Mar;56(2):103-5 - PubMed
  20. Exp Oncol. 2012 Jul;34(2):101-6 - PubMed

Publication Types